Category Archives: MS Treatment

05.20.14- Multiple Sclerosis Updated on Nutrition, Self Aspects and MS Treatment Options Nutrition and Self Aspects, MS Treatment Options Adherence, Compliance, Switching, Brian Steingo, MD -- MS Neurology May 20th, 2014 - Miami, Fl. 33172 Websit... By: MSViewsandNews … Continue reading →

In case Proven MS Treatment By Dr Gary Levin | 1:36 Conversion! you would like Goto http://bit.ly/1gYK5Ot Dr Gary M Levin M.d Herbal Remedies Award Winner. Has His Own Private Medical Practice For 30 Years Releases His Top Converting ... By: pstilnas … Continue reading →

PUBLIC RELEASE DATE: 4-Jun-2014 Contact: Arney Rosenblat arney.rosenblat@nmss.org 212-476-0436 National Multiple Sclerosis Society Multiple sclerosis manifests itself in many different ways and different courses. A recent effort to fine-tune descriptions or phenotypes -- of MS was undertaken by an international team of leaders in MS research and clinical care. The results of this effort by the International Advisory Committee on Clinical Trials in MS, including recommendations for more research, has just been published (Neurology 2014;83:1). The volunteer Committee is jointly supported by the National MS Society and the European Committee for Treatment and Research in MS (ECTRIMS). "Having better definitions of different types of MS would greatly facilitate research studies, communications between people with MS and their healthcare providers, and treatment decisions," noted Timothy Coetzee, PhD, Chief Advocacy, Services and Research Officer of the National MS Society. In 1996 the Committee had developed consensus around descriptions of the courses of MS to facilitate research in MS and so that researchers and clinicians around the world would have a common understanding of the types of MS discussed in publications and in the clinic. This consensus highlighted four courses of MS -- relapsing-remitting, secondary progressive, primary progressive, and progressive relapsing. While these … Continue reading →

A new Canadian study is casting doubt on the link between blocked neck veins and multiple sclerosis, after finding no difference in the proportion of abnormalities in the veins of MS patients and healthy controls. The study, published Monday in The Canadian Medical Association Journal, found no link between chronic cerebrospinal venous insufficiency (CCSVI) and MS. Using ultrasound and MRI technology, University of Calgary neurologist Dr. Fiona Costello and her colleagues tested the criteria used to diagnose a patient with CCSVI on a group of MS patients and healthy controls. They compared the ultrasound results of 120 patients and 60 controls and found a "high" proportion of both groups met one or more of the criteria required for a CCSVI diagnosis. Their results showed that 58 per cent of MS patients and 63 per cent of the healthy controls met one or more of the proposed criteria. "We detected no differences in the proportion of venous outflow abnormalities between patients with multiple sclerosis and healthy controls," the study's authors conclude. "Moreover, our study revealed significant methodologic concerns regarding the proposed diagnostic criteria for chronic cerebrospinal venous insufficiency that challenge their validity." Dr. Paolo Zamboni first put forth his theory that … Continue reading →

A new Canadian study is casting doubt on the link between blocked neck veins and multiple sclerosis, after finding no difference in the proportion of abnormalities in the veins of MS patients and healthy controls. The study, published Monday in The Canadian Medical Association Journal, found no link between chronic cerebrospinal venous insufficiency (CCSVI) and MS. Using ultrasound and MRI technology, University of Calgary neurologist Dr. Fiona Costello and her colleagues tested the criteria used to diagnose a patient with CCSVI on a group of MS patients and healthy controls. They compared the ultrasound results of 120 patients and 60 controls and found a "high" proportion of both groups met one or more of the criteria required for a CCSVI diagnosis. Their results showed that 58 per cent of MS patients and 63 per cent of the healthy controls met one or more of the proposed criteria. "We detected no differences in the proportion of venous outflow abnormalities between patients with multiple sclerosis and healthy controls," the study's authors conclude. "Moreover, our study revealed significant methodologic concerns regarding the proposed diagnostic criteria for chronic cerebrospinal venous insufficiency that challenge their validity." Dr. Paolo Zamboni first put forth his theory that … Continue reading →

Listen Story audio 4min 44sec For decades, women with multiple sclerosis have noticed that they tend to do better while they are pregnant. That has led to an experimental drug for the disease that's based on a hormone associated with pregnancy. The hormone is a form of estrogen called estriol. It's abundant in a woman's body only when she is pregnant. Adding estriol to treatment with an existing MS drug cut relapses by 47 percent in a study of 158 women presented at the American Academy of Neurology meeting in April. The result is "quite remarkable," says Rhonda Voskuhl, an author of the study and a neurologist at the University of California, Los Angeles. It suggests that estriol could greatly enhance the effectiveness of current MS drugs, Voskuhl says. Those drugs, which are designed to modulate the immune system, can cost up to $60,000 a year. Multiple sclerosis is a disease that damages the myelin sheath covering nerve fibers. Researchers believe the damage is caused at least in part because the body's own immune cells begin attacking myelin. About 400,000 people in the United States have multiple sclerosis, with symptoms ranging from muscle weakness or paralysis to difficulty thinking. The … Continue reading →

Boise, ID (PRWEB) May 30, 2014 Naturopathix, Inc. appoints Taiwans Teh Yuh Trading Company as its Asia distributor for ZymaDerm the most widely used painless, safe and inexpensive natural topical treatment for molluscum contagiosum In the United States. The distribution agreement grew out of Briant Burke, MD, MS, founder and medical director of Naturopathix, participating in an Asia Trade Mission organized by Idaho Governor "Butch" Otter. Although ZymaDerm can be ordered online for shipping to Asia says Dr. Burke, the new distribution agreement with Teh Yuh Trading seeks to attract drug stores throughout Asia to order and stock ZymaDerm for their local markets. Many in Asia have been ordering ZymaDerm at Naturopathix.com, and through leading online retailers that include Drugstore.com, Amazon.com, Walgreens.com, Walmart.com and CVS.com We look forward to bringing parents in Asia our simple and effective all natural molluscum treatment to avoid using expensive, painful, and usually ineffective treatments on their children, continues Dr. Burke. ZymaDerm is the most widely used painless and inexpensive natural treatment in the United States. Since its introduction in 2003, ZymaDerm has enabled over half a million people to quickly be rid of the unsightly and highly contagious molluscum skin bumps and reduce the … Continue reading →

By Cyndi Root Bayer announced in a press release that it has begun marketing a new injection system in Germany for the Bluetooth-enabled administration and monitoring of Betaferon. The BETACONNECT auto-injector is for the treatment of multiple sclerosis (MS). The system uses the myBETAapp to upload data to a smartphone or computer using a Bluetooth or USB connection. Bayer collaborated with Bang & Olufsen Medicom on BETACONNECT and associated software systems. Prof. V. Limmroth, Chairman of the Department of Neurology at Cologne General Hospital, in Germany said, By introducing the first MS autoinjector with Bluetooth capabilities, Bayer is helping patients who use Betaferon with a true innovation to gather in real time important information on their MS treatment and, if they choose, to seamlessly share the data with their healthcare providers. BETACONNECT Autoinjector The BETACONNECT autoinjector will help patients optimize their treatment as the system provides notifications based on patient preferences, such as audio or visual reminders, and feedback on injection depth and speed. Patients can opt to share the information with their healthcare providers to further improve treatment. The injector electronically automates the Betaferon injection while the myBETAapp mediates the flow of information from the device to the patients … Continue reading →

Scientists have spent 25 years developing treatment at Cambridge Alemtuzumab infusion is given in two short courses over two years Despite costing 56,000, NICE has ruled treatment is cost-effective By Jenny Hope Published: 19:16 EST, 27 May 2014 | Updated: 07:13 EST, 28 May 2014 4,912 shares 45 View comments Landmark discovery: The brain of someone with MS, which can leave sufferers unable to walk - but new treatment could reverse the effects of the disease A new treatment for Multiple Sclerosis not only stops the disease from advancing but may help patients recover from disability. Remarkable results for the drug alemtuzumab mean it has been approved for use on the NHS and is now available in England. Originally a pioneering cancer therapy, Cambridge University scientists have spent almost 25 years developing it as a treatment for MS sufferers. Read more: NHS patients to get new Multiple Sclerosis drug Alemtuzumab … Continue reading →

Contact Information Available for logged-in reporters only EMBARGOED UNTIL WEDNESDAY, MAY 28 at 4:00PM (EST) Contact: Elizabeth Dowling Mount Sinai Press Office (212) 2419200 NewsMedia@mssm.edu Mount Sinai Researchers Lead International Advisory Committee To Define The Clinical Course of Multiple Sclerosis Re-examination of standardized multiple sclerosis descriptions published in 1996 to influence future research studies and clinical practice (NEW YORK May 28) Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment for clinical trials, and treatment decision-making. Researchers at Icahn School of Medicine at Mount Sinai, part of the International Committee on Clinical Trials of MS, collaborated to re-examine the standardized MS clinical course descriptions originally published in 1996 and recommend refined phenotype descriptions that include improved clinical descriptive terminology, MRI and other imaging techniques, analysis of fluid biomarkers and neurophysiology. The proposed 2013 revisions will appear in the May 28, 2014, online issue of Neurology, the medical journal of the American Academy of Neurology. Our goal for modifying the 1996 definitions is to better characterize patients with MS and provide a framework for both clinical research and ongoing clinical care, says Fred D. Lublin, MD, Director of the Corinne Goldsmith Dickinson Center … Continue reading →